Sumana F. Gangi
Expertise in
14
conditions

Dr. Sumana F. Gangi

Endocrinology
Southern Endocrinology Associates
7801 Lakeview Parkway, Suite 130, 
Rowlett, TX 
Accepting New Patients
Offers Telehealth
Referral required
Before you request
Expertise in
14
conditions
Southern Endocrinology Associates
7801 Lakeview Parkway, Suite 130, 
Rowlett, TX 

Overview

Sumana Gangi is an Endocrinologist practicing medicine in Rowlett, Texas.

Dr. Gangi is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Type 2 Diabetes (T2D), Hypothyroidism, Obesity in Children, and Thyroid Storm.

Dr. Gangi is board certified in Endocrinology, Diabetes And Metabolism- American Board Of Internal Medicine, Endocrinology Diabetes And Metabolism- American Board Of Internal Med/Endocrinology, Diabetes And Metabolism, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 10 clinical trials. Dr. Gangi is currently accepting new patients.

Specialties

Endocrinology

Licenses

Internal Medicine in NJ

Board Certifications

Endocrinology, Diabetes And Metabolism- American Board Of Internal Medicine
Endocrinology Diabetes And Metabolism- American Board Of Internal Med/Endocrinology, Diabetes And Metabolism
Internal Medicine- American Board Of Internal Med
Internal Medicine- American Board Of Internal Medicine

Fellowships

Hepatology, UMDNJ RW Johnson Medical School - 2004
Hepatology, UMDNJ-New Jersey Medical School - 2004
Endocrinology, University of Buffalo - 2006
State Univ of NY at Buffalo School of Medicine - 2006

Hospital Affiliations

Baylor Scott & White Medical Center - Lake Pointe
Baylor Scott & White Medical Center - Centennial
Baylor Scott & White Medical Center - Sunnyvale
Texas Health Presbyterian Hospital Dallas
Baylor Scott And White Medical Center Sunnyvale
Medical City Plano
Hunt Regional Medical Center
Baylor Scott And White Medical Center Lake Pointe

Languages Spoken

English
Hindi
Spanish
Telugu

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
EMI Health
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 28 Less Insurance Carriers -

Locations

Southern Endocrinology Associates
7801 Lakeview Parkway, Suite 130, Rowlett, TX 75088
Other Locations
Southern Endocrinology and Diabetes Associates
1621 N Beltline Rd, Ste A, Mesquite, TX 75149
Southern Endocrinology & Diabetes Associates
7700 Lakeview Pkwy, Ste 400A, Rowlett, TX 75088

Additional Areas of Focus

Dr. Gangi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: July 08, 2026
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3437943
Study Phase: Phase 2
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drugs: LY3437943, Dulaglutide
Study Phase: Phase 2
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: November 02, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
Enrollment Status: Completed
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100).
Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100).
Journal: Clinical diabetes : a publication of the American Diabetes Association
Published: July 17, 2023
Similar Doctors
Expertise in
13
conditions
Dr. Abhimanyu Garg
Endocrinology
Expertise in
13
conditions
Dr. Abhimanyu Garg
Endocrinology
Referral required
Before you request

Office

2001 Inwood Rd, 
Dallas, TX 
 (19.7 miles away)
214-645-2800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Abhimanyu Garg is an Endocrinologist practicing medicine in Dallas, Texas. Dr. Garg is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Acrorenal Mandibular Syndrome, Familial Partial Lipodystrophy, Congenital Generalized Lipodystrophy, Familial Hypertriglyceridemia, and Gastric Bypass. Dr. Garg is currently accepting new patients.

Expertise in
62
conditions
Dr. Oksana Hamidi
Endocrinology
Expertise in
62
conditions
Dr. Oksana Hamidi
Endocrinology
Referral required
Before you request

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (19.6 miles away)
216-648-0600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Oksana Hamidi is an Endocrinologist practicing medicine in Dallas, Texas. Dr. Hamidi is highly rated in 62 conditions, according to our data. Her clinical expertise encompasses Cushing's syndrome, Pheochromocytoma, Adrenal Cancer, Hormone Replacement Therapy (HRT), and Liver Embolization. Dr. Hamidi is currently accepting new patients.

Expertise in
29
conditions
Dr. Naim M. Maalouf
Endocrinology
Expertise in
29
conditions
Dr. Naim M. Maalouf
Endocrinology
Referral required
Before you request

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (19.6 miles away)
214-645-2870
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Naim Maalouf is an Endocrinologist practicing medicine in Dallas, Texas. Dr. Maalouf is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Milk-Alkali Syndrome, Hypercalcemia, Hyperparathyroidism, Parathyroidectomy, and Ureteroscopy. Dr. Maalouf is currently accepting new patients.

Frequently Asked Questions about Dr. Sumana F. Gangi

How do I make an appointment with Dr. Sumana F. Gangi?

You can book an appointment with Dr. Sumana F. Gangi by calling their office at 972-412-6969. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sumana F. Gangi a top-rated expert for Type 2 Diabetes (T2D)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sumana F. Gangi is classified as an Distinguished expert for Type 2 Diabetes (T2D), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sumana F. Gangi specialize in?

While Dr. Sumana F. Gangi is a Endocrinology, they have specific expertise in Type 2 Diabetes (T2D), Hypothyroidism, and Obesity in Children. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Sumana F. Gangi participate in research or clinical trials?

Yes. Dr. Sumana F. Gangi has published 1 articles and abstracts on conditions like Type 2 Diabetes (T2D). You can view a list of Dr. Sumana F. Gangi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sumana F. Gangi accept my insurance?

Dr. Sumana F. Gangi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 972-412-6969 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gangi's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile